Acyclic Glutarimide PROTAC Precursors Enable Controlled Protein Degradation and Expand Cereblon Ligand Space
Year: 2026
Type: editorial
Abstract: Targeted protein degradation continues to reshape therapeutic strategy, yet the structural constraints of cereblon (CRBN) ligand chemistry limit broader application. Patent application WO 2026/043898 A1 discloses acyclic glutarimide-based precursors that undergo in situ cyclization to generate active degraders. This prodrug-like strategy enables temporally controlled CRBN engagement, enhances conjugation compatibility, and expands the degrader design space across oncology and related indications.
Source: ACS Medicinal Chemistry Letters
Authors: Anna C. Renner, Robert B. Kargbo
Institution: North Dakota State University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7154391770